TOP-128-YI Efficacy of WNTinib, a novel selective therapeutic for CTNNB1mutant tumors, in preclinical models of hepatoblastoma

Ugne Balaseviciute; Júlia Huguet‐Pradell; Jordi Abril‐Fornaguera; Elisa Fernández-Martínez; Albert Gris‐Oliver; Roser Pinyol; Alex Rialdi; Agavni Mesropian; Gulay Ulukaya; Dan Hasson; Ieva Keraite; Swan N. Thung; Ernesto Guccione; Josep M. Llovet

doi:10.1016/s0168-8278(25)01230-9

Related publications

Article2024

FRI-467 Efficacy of WNTinib, a novel selective therapeutic for CTNNB1 mutant tumors, in preclinical models of hepatoblastoma

Ugne Balaseviciute, Jordi Abril‐Fornaguera, Júlia Huguet‐Pradell, Alex Rialdi, Elisa Fernández-Martínez, Albert Gris‐Oliver, Agavni Mesropian, Gulay Ulukaya, Dan Hasson, Ieva Keraite, Roser Pinyol, Swan N. Thung, Ernesto Guccione, Josep M. Llovet

Journal of Hepatology

Article2024

110 (PB098): Efficacy of WNTinib, a novel selective therapeutic for CTNNB1-mutant tumors, in preclinical models of hepatoblastoma

Ugne Balaseviciute, Jordi Abril‐Fornaguera, Júlia Huguet‐Pradell, Eduardo Fernández‐Martínez, Albert Gris‐Oliver, Alexander Rialdi, Agavni Mesropian, Gulay Ulukaya, Danielle M. Hasson, Ieva Keraite, Roser Pinyol, S N Thung, Ernesto Guccione, Josep M. Llovet

European Journal of Cancer

Article2025

THU-077-YI E7386 enhances lenvatinib’s antitumor efficacy and upregulates ATF4 signalling in preclinical models and human hepatocellular carcinoma

Agavni Mesropian, Albert Gris‐Oliver, Ugne Balaseviciute, Martí Torres-Marcen, Jordi Abril‐Fornaguera, Marta Piqué‐Gili, David Camell, Judit Peix, Elisa Fernández-Martínez, Júlia Huguet‐Pradell, Ieva Keraite, Roger Esteban-Fabró, Takayuki Kimura, Alka A. Potdar, Marina Bárcena‐Varela, Katherine E. Lindblad, Amaia Lujambio, Ernesto Guccione, Swan N. Thung, Daniela Sia, Roser Pinyol, Josep M. Llovet

Article2024

TOP-507-YI Single-cell RNA sequencing-derived gene signatures reveal distinct response mechanisms to atezolizumab + bevacizumab in advanced hepatocellular carcinoma

Sarah Cappuyns, Marta Piqué‐Gili, Roger Esteban-Fabró, Gino Philips, Roser Pinyol, Albert Gris‐Oliver, Vincent Vandecaveye, Jordi Abril‐Fornaguera, Carla Montironi, Laia Bassaganyas, Judit Peix, Marcus Zeitlhoefler, Agavni Mesropian, Júlia Huguet‐Pradell, Philipp K. Haber, Rephael Mohr, Tim Meyer, Helen L. Reeves, Julien Edeline, Fabian Finkelmeier, Jörg Trojan, Peter R. Galle,

Article2018

Precision medicine targeting disrupted IGF signaling in hepatoblastoma

Olga Kuchuk, Nicholas K. Akers, Daniela Sia, Marina Simon‐Coma, Jose Carrillo, Iris Martinez-Quetglas, Martina Gambato, Laura Royo, Stephen Yoo, M.A. Buendia, Stefano Cairo, Jinhong Zhu, Vincenzo Mazzaferro, Bojan Losic, Carolina Armengol, Josep M. Llovet

Journal of Hepatology

TOP-128-YI Efficacy of WNTinib, a novel selective therapeutic for CTNNB1mutant tumors, in preclinical models of hepatoblastoma

Abstract

Discussion(0)

Related publications

FRI-467 Efficacy of WNTinib, a novel selective therapeutic for CTNNB1 mutant tumors, in preclinical models of hepatoblastoma

110 (PB098): Efficacy of WNTinib, a novel selective therapeutic for CTNNB1-mutant tumors, in preclinical models of hepatoblastoma

THU-077-YI E7386 enhances lenvatinib’s antitumor efficacy and upregulates ATF4 signalling in preclinical models and human hepatocellular carcinoma

TOP-507-YI Single-cell RNA sequencing-derived gene signatures reveal distinct response mechanisms to atezolizumab + bevacizumab in advanced hepatocellular carcinoma

Precision medicine targeting disrupted IGF signaling in hepatoblastoma